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Background: Tumor necrosis factor (TNF)-α inhibitors are increasingly being used in inflammatory bowel disease
(IBD). Because this chronic intestinal disorder often affects women of fertile age, it is essential to assess the effect of
biologics on pregnancy outcome.
Methods: We performed a systematic review of the English-language literature to investigate if treatment with
TNF-α blockers during pregnancy in women with IBD increases the risk of spontaneous abortions, preterm delivery,
stillbirth, low birth weight, congenital malformations, or risk of infections in the offspring. Of 552 articles and
abstracts reviewed, 58 articles or abstracts with unique content were identified and included in this systematic
review. However, most presentations were case reports or case series supplied by a limited number of
observational studies. No randomized controlled studies were available.
Results: TNF-α inhibitors do not seem to affect either outcome of pregnancy in mothers with IBD, or the outcome
in the offspring (congenital malformations and immunosuppression). Further, recent data have not identified any
increased risk of infections in the first year of life in the offspring of mothers who received biologics, even in
combination with immunomodulators (thiopurines).
Conclusions: From the present systematic review, no association was found between administration of TNF
inhibitors for IBD during pregnancy and adverse pregnancy outcome or congenital abnormalities. Further, no
increased relative risk of infections has been reported in the first year of life in offspring of mothers who received
biologics. Biologics should be discontinued during pregnancy solely if the IBD is in remission using the same
stopping criteria as for patients with IBD in general, as uncontrolled activity of IBD may expose the mother and
child to a risk greater than those only potentially coming from the use of TNF-α inhibitors. In such cases,
inoculation of the offspring with live vaccines is contraindicated until the biologic agent is no longer detectable in
the child’s circulation.
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Biologics are effective and increasingly used in the treat-
ment of inflammatory bowel disease (IBD), of which
Crohn’s disease (CD) and ulcerative colitis (UC) are the
two main types. As the peak incidence of IBD overlaps
with the prime reproductive years, information on the
effects of biologics on pregnancy outcome (including
fetal harm) is essential in order to give appropriate ad-
vice to women of childbearing age who require treat-
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reproduction in any medium, provided the orIn general, women with IBD are advised to conceive at
quiescent stages of their disease, as this reduces the risk
of obstetric complications (for example, preterm delivery
and low birth weight) [1-5]. Effective control of disease
activity using a wide range of medications, including bio-
logics, is vitally important during pregnancy [6,7].
The most commonly used biologics in IBD are
infliximab (IFX), a chimeric IgG1 monoclonal antibody;
adalimumab (ADA), a human monoclonal IgG1 anti-
body; and certolizumab pegol (CZP), a pegylated Fab
fragment of a humanized IgG4 isotype monoclonal anti-
body [8]. Recently, golimumab (GLM), also a human
monoclonal IgG1 antibody, has been added to the list.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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drugs by the US Food and Drugs Administration (FDA)
[9], meaning that animal reproduction studies have not
shown any risk to the fetus, but there are no adequate and
well-controlled studies in pregnant women.
In the clinical scenarios of a woman with IBD on bio-
logic therapy becoming pregnant, or when biologic treat-
ment is being considered in a pregnant woman with
active IBD, decisions are made on a case-by-case basis
because the short-term and long-term implications of
exposure to biologic agents have not yet been investi-
gated systematically. Although no comparative effective-
ness data exist to support the strategy, it has been
common practice at many IBD centers to continue bio-
logics through the second trimester of pregnancy [10],
as the transplacental transfer of IgG begins around week
20 and increases thereafter, especially during the third
trimester [11]. In accordance with this practice, IFX and
ADA are discontinued around week 30 of pregnancy
[12], and in patients with active IBD, it has been sug-
gested to bridge therapy with glucocorticoids to control
disease activity until delivery [13-16]. This approach has
the benefit of minimizing the break from treatment with
biologic agents and perhaps decreasing the risk of im-
munogenicity [8] (that is, the risk of hypersensitivity re-
actions or loss of response once the biologic is
reintroduced post-partum). However, CZP may differ
from the other tumor necrosis factor (TNF)-α blockers
used in IBD, as it is a Fab fragment of a monoclonal
antibody, which is not transported across the placenta
and therefore, it may not be necessary to discontinue
this drug in the third trimester [17].
However, at present there are no definitive conclusions
concerning what could be one of the most important
therapeutic decision-making settings from the viewpoint of
risk-benefit analysis. Thus, the decision whether to use bio-
logics during pregnancy might be regarded as an example
in which it is considered most prudent to err on the side of
caution, especially as it is still unknown what levels in the
serum of TNF inhibitors used to treat a mother with IBD
will be safe or harmful for the fetus or newborn.
The aim of this study was to perform a systematic re-
view of the available literature on the risk of adverse
birth outcomes related to IBD after maternal exposure
to IFX, ADA, or CZP, in order to improve evidence-
based informed choice and clinical decision-making dur-
ing pregnancy, especially in the third trimester. Data
about use of GLM in IBD pregnancies are currently un-
available, as it has only recently been approved for UC.
Methods
Ethics approval
This study was an analysis of published data, which did
not require ethics committee approval.Search strategy
A systematic review was performed according to the
guidelines established by the Meta-analysis of Observa-
tional Studies and Epidemiology Group (MOOSE cri-
teria) [18]. The databases searched (January 1998 to May
2013) were MedLine, EMBASE, the Cochrane Library,
and the homepages of the FDA and the European Medi-
cines Agency (EMA), using the combinations of the fol-
lowing Medical Subject Heading (MeSH) search terms:
(inflammatory bowel disease OR inflammatory bowel
diseases OR Crohn’s disease OR ulcerative colitis) AND
biologics OR biologic products OR infliximab OR
adalimumab OR golimumab OR certolizumab. This was
again combined with either pregnancy OR newborn OR
lactation OR breast feeding OR infant. No authors were
contacted.
Selection criteria
We wanted to include all randomized controlled trials,
observational studies, case series, and case reports
evaluating pregnancy outcomes of women with IBD
treated with TNF-α inhibitors (IFX, ADA, GLM, or
CZP) during any trimester of pregnancy, including the
90 day periconceptional period. Outcome assessment
included miscarriages (spontaneous abortions), pre-
term delivery, stillbirth, low birth weight, and/or con-
genital malformations, and if data were available, it
also included assessment of infections in the offspring.
Only abstracts or articles published in English were
considered. Figure 1 shows the flowchart of the study
screening process.
Data extraction
Two authors (OHN and TJ) independently identified
candidate articles from the results of the initial search,
based on the title and abstract. Subsequently, both au-
thors independently reviewed the full text of candidate
articles to identify interventions and assess study quality.
In cases of any discrepancies between the independent
searchers, these were resolved in consensus with the
third author (EVL).
The reference lists of relevant articles were hand-
searched to identify additional studies. Further, abstracts
from the meetings of American Gastroenterological As-
sociation (Digestive Disease Week), American College of
Gastroenterology, and the European Crohn’s and Colitis
Organisation from 1998 to May 2013 were searched
manually for relevant abstracts based on the aforemen-
tioned search terms.
Summarization of data
The search yielded a total of 58 studies (36 articles and
22 abstracts) that met the inclusion criteria (Table 1).
The studies comprised 33 case reports, 21 case series,
Studies retrieved 
through electronic and 
subsequent hand search 
(n=552)
Excluded due to no 
relevance, e.g., other 
diseases or animals 
(n=49)
Excluded due to non-
English language (n=74)
Exclusion of reviews and 
articles without patient 
cases (n=335)
Studies excluded due to:
-Repeated patient 
description (n=36)
Second pass review of 
studies (n=429)
Studies included in final 
analysis (n=58)
Detailed evaluation of 
studies n=94
First pass review of 
studies (n=478)
Figure 1 Flowchart of the study screening process.
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groups. No controlled randomized studies were identi-
fied. The total number of pregnant women with IBD
who were exposed to anti-TNF agents was at least 1,533
(one study with 289 pregnancies included other diseases
and did not specify the number of women with IBD
[19]). The bias of the present study was that only non-
English studies were excluded.
Results
Infliximab
In the early days of biologic treatment for IBD, IFX was
reported to be associated with adverse pregnancy out-
comes in some case reports [20,21], but not in others
[22-27], and in case series where IFX was administered
throughout pregnancy to maintain remission in IBD, no
harm to the fetus/child was reported [16,19,28-34]. Fur-
thermore, larger and subsequent studies did not report
any increased risk for adverse events compared with un-
exposed IBD pregnancies [12,17,35-49]. In a study on
pregnancies exposed to IFX, Zelinkova et al. observed
one adverse event (polydactyly), actually reported on
two occasions [12,50]. In this particular case, the mother
of the infant had also received methotrexate (MTX) 2months prior to conception [12,50]. MTX is a drug clas-
sified as ‘X’ by the FDA; that is, a drug for which studies
in animals or humans have shown fetal abnormalities
and/or for which there is positive evidence of human
fetal risk, based on adverse reaction data from investiga-
tional or marketing experience, and for which the risks
involved in use of the drug in pregnant women clearly
outweigh the potential benefits [9]. However, polydactyly
is an uncommon disorder; it is not usually seen as the
only complication to MTX treatment, but is more often
present together with other abnormalities [50].
The first series studying intentional IFX administration
throughout pregnancy examined outcomes in 10 women
with active CD, and all ended in live births [32]. Of these
10 births, there were 3 cases of premature birth and 1
case with low birth weight, findings that were not unex-
pected in women with CD that was sufficiently severe to
require IFX treatment. No congenital abnormalities were
observed 6 months post-partum [32].
The four largest studies providing data on the safety of
IFX in an IBD population are from the Therapy Re-
source Evaluation Assessment Tool (TREAT) registry
[36], a pregnancy safety database maintained by the
manufacturer of IFX [49], the Pregnancy in Inflamma-
tory Bowel Disease and Neonatal Outcomes (PIANO)
registry [51] and the Groupe d’Etude Thérapeutique des
Affections Inflammatoires du Tube Digestif (GETAID)
collaboration [52].
The TREAT registry is a prospective study of North
American patients with CD. As of February 2010, there
were 6,273 patients in the registry, and 142 pregnancies
with IFX exposure were reported. The risk of fetal
malformations was no higher than in the general popu-
lation [36], and a more detailed analysis of pregnancies
in the TREAT registry is under way [36].
The IFX Safety Database is a retrospective data-
collection instrument set up by the manufacturer of IFX
(Centocor, now Janssen Biotech) to study women with
rheumatoid arthritis or CD exposed to IFX before or
during pregnancy. There were 96 women with direct ex-
posure to IFX who gave birth to 100 children; however,
in most case, IFX treatment was discontinued in the first
trimester of pregnancy. The rates of adverse outcomes
were not different from that expected in the general
population [49].
Preliminary data from the US national prospective
PIANO registry has recently been disclosed [53]. A total
of 1,232 women with IBD were enrolled as of April 1,
2013, of whom 357 women received biologics, including
during the third trimester, and an additional 109 women
received a combination of thiopurines and biologics [53].
Adverse pregnancy outcomes such as spontaneous abor-
tions, preterm birth, low birth weight, and congenital ab-
normalities were evaluated. A slightly higher relative risk
Table 1 Published studies on the use of TNF-α blockers in IBD pregnancies
Author Year Anti-TNF Stage of pregnancy Study type Mode of delivery Outcome of pregnancies
James [25] 2001 IFX P(T2) Case report Unknown Normal, healthy, full term
Srinivasan [21] 2001 IFX PC/P(T1) Case report Unknown Premature, preterm, LBW. Adverse outcome:
intracerebral and intrapulmonary bleeding
followed by death 3 days later
(metronidazole + azathioprine + 5-ASA was
also administered in pregnancy for treatment
of flare and fistulae)
Bank et al. [24] 2002 IFX P(T1-T2) Case report Unknown Normal, healthy, full term (correspondence
with authors)
Burt et al. [27] 2003 IFX PC Case report C-section Normal, healthy, preterm (36 weeks)
Katz et al. [49] 2004 IFX 53/96 PC; 58/96 P(T1);
6/96 unknown
Case series from Infliximab
Safety Database (82 CD, one
UC, 10 RA, 3 unknown); 96
women, 72 births
Unknown 64/96 were live births (1 preterm death at 24
week, 1 full-term with tetralogy of Fallot, 1
perinatal sepsis, 1 intestinal malrotation, 1
developmental delay); 4 pregnancies ended
with twins. 14/96 were miscarriages, 18/96
were therapeutic terminations
Mahadevan et al. [32] 2005 IFX 9/10 PC; 8/10 P(T2);
8/10 P(T3); 7/10 PP
Case series (n = 10 women) 8/10 C-section, 2/10 Vaginal 3/10 were preterm, 1/10 were LBW, 2/10
were neonatal illnesses, which resolved. All
normal at follow-up
Tursi [34] 2006 IFX PC/P(T1-T3)/PP Case report Unknown Normal, healthy, preterm (36 weeks)
Xirouchakis et al. [64] 2006 IFX PC/P(T1) Case report Vaginal Normal, healthy, full term
Vasiliauskas et al. [16] 2006 IFX (10 mg/kg
body weight)
PC/P(T1-T3) Case report Vaginal Normal, healthy, full term
Mahadevan et al. [28] 2007 IFX P(T1-T3) Case series (n = 5) 4 vaginal/1 C-section Normal, healthy, full term
Malgarinos et al. [29] 2007 IFX PC/P(T1-T3) Case report Unknown Normal, healthy, preterm
Angelucci et al. [26] 2008 IFX P(T1) Case report C-section Normal, healthy, full term
Palmer et al. [20] 2008 IFX P(T2-T3) Case report Unknown Intra-uterine fetal death due to placental
abruption or intra-uterine infection
Stengel et al. [33] 2008 IFX PC/P(T1-T3) Case report C-section Normal, healthy, full term
Kane et al. [68] 2009 IFX 2 PC/P(T1-T3), 1 P(T2) Case series (3 women) 2 vaginal, 1 C-section 3 normal, healthy, full term
Hou et al. [14] 2009 IFX PC/p(T1-T3) Case report Vaginal Normal, healthy, full term
Arai et al. [23] 2010 IFX P(T2-T3) Case report Unknown Normal, healthy, full term
Epping et al. [66] 2010 IFX PC/P(T1-T3) Case report Unknown Normal, healthy, full term
Angelucci et al. [65] 2010 IFX PC/P(T1) Case report C-section Normal, healthy, preterm (31 weeks)
Correia et al. [30] 2010 IFX PC/P(T1-T3) 2 case reports C-section Normal, healthy; 1 preterm (31 weeks)
Molnár et al. [47] 2010 IFX PC/P(T1-T3) Case report Unknown Normal, healthy, full term
Cheent et al. [63] 2010 IFX (10 mg/kg
body weight)
PC/P(T1-T3) Case report Vaginal Healthy, full term, no malformations



















Table 1 Published studies on the use of TNF-α blockers in IBD pregnancies (Continued)
Abdul Wahab et al. [40] 2011 IFX P(T2-T3) Case report Unknown Normal, healthy, full term
Kozeluhova [41] 2011 IFX PC/P(T1-T3) Case report Unknown Normal, healthy, full term
Chaparro et al. [45] 2011 IFX PC/P(T1-T3) Case report C-section Normal, healthy, full term
Naganuma et al. [67] 2011 IFX PC/P(T1-3) Case series (3 women) Unknown All healthy, full term, 1 low birth
weight, no malformations
Steenholdt et al. [22] 2012 IFX PC/P(T1-T2) Case report Unknown Normal, healthy, full term
Arguelles-Arias et al. [42] 2012 IFX PC/P(T1-T3) Case series (12 women) 8 vaginal, 4 C-sections 12 healthy children
Lichtenstein et al. [36] 2012 IFX 142 reported
pregnancies
Case series (analysis of data from
TREAT registry)
Unknown The vast majority of babies (92.4%)
were healthy with no defects or
other adverse events
Snoeckx et al. [38] 2013 IFX PC/P(T1-T3) Case series (556 pregnancies) Unknown There were 58 miscarriages, 38 elective
abortions, 7 stillbirths, and 453 live births
Vesga et al. [80] 2005 ADA PC/P(T1-T3)/PP Case report C-section Normal, healthy, full term
Coburn et al. [77] 2006 ADA P(T2; T3) Case report Unknown Normal, healthy, full term
Mishkin et al. [79] 2006 ADA PC/P(T1-T3) Case report Vaginal Normal, healthy, full term
Chambers et al. [75] 2006 ADA PC/P(T1) Case series (5 women) Unknown All full-term live births. No malformations
Bosworth et al. [71] 2007 ADA PC/P(T1-T3) Case report C-section Normal, healthy, full term
Johnson et al. [72] 2009 ADA PC/P(T1-T3) Case-controlled study 34 women
and 45 controls (OTIS)
Unknown 29 live-born (1 with undescended testicle
+ 1 with microencephaly); 5 spontaneous
abortions. Two major structural defects
in control group
Jürgens et al. [78] 2010 ADA PC/P(T1) Case report Vaginal Healthy, full term
Ben-Horin et al. [74] 2010 ADA PC/P(T1-3) Case report Vaginal Healthy, full term
Abdul Wahab et al. [73] 2011 ADA PC/P(T1-T3) Case report C-section Twins, normal, healthy, full term
Mahadevan et al. [76] 2011 ADA PC/P(T1-T3) Case series (5 women) 2 vaginal 3 C-sections Healthy (one infant developed pulmonary
edema, but recovered fully)
Kane et al. [31] 2009 CZP Unknown (UCB
data on file)
Case series (16 women) Unknown 4 healthy, full term; 1 small for gestational
age; and 2 lost to follow-up. 8 induced
abortions amd 1 spontaneous abortion
Mahadevan et al. [85] 2009 CZP P(T2; T3)/PP Case report Unknown Healthy, full term, no malformations
Oussalah et al. [86] 2009 CZP PC/P(T1; T3) Case report Vaginal Normal, healthy, full term. Adverse outcome
in 1 case: bleeding 7 days post-partum,
secondary to cotyledon retention
Steinberg et al. [84] 2010 CZP P(T2-T3) Case report C-section Healthy, full term, no malformations
Mahadevan et al. [87] 2012 CZP PC/P(T1-T3) Case series (139 pregnancies including
17 with rheumatoid arthritis)
Unknown 21 miscarriages, 15 elective abortions, and
103 live births (2 with congenital
abnormalities: 1 with mild unilateral
hydronephrosis and 1 with vesicouretic reflux)
Slama et al. [19] 2010 IFX/ADA PC/P(T1-T3) Case series (289 pregnancies including
other diseases than IBD)
Unknown No increased risk of adverse pregnancy




















Table 1 Published studies on the use of TNF-α blockers in IBD pregnancies (Continued)
Dunne et al. [46] 2011 IFX/ADA PC/P(T1-T3) 15 case series (15 women) Unknown 9 terminated pregnancies at study end. All
live births were healthy, with two sets
of twins
Schnitzler et al. [54] 2011 IFX/ADA PC and/or P(T1)
and/or P(T2)
Case-controlled study (35 women
with 42 pregnancies (35 IFX + 7 ADA)
versus 101 pregnancies before IBD/
treatment and 56 matched pregnancies
in healthy controls)
Unknown 10 abortions (1 trisomy 18, 1 elective), 1
stillbirth (umbilical strangulation), 32 live
births: 8/32 premature, 6/32 low birth weight.
All children were born healthy but one child
with necrotizing enterocolitis died at 13 days
of age (mother required treatment for severe
asthma and CD during T3)
Machková et al. [43] 2012 IFX/ADA PC/P(T1-T3) Case series (33 pregnancies in 31 women) Unknown 5/33 pregnancies ongoing. 24/28 healthy
children (4/24 preterm), 3/24 spontaneous
abortions, and 1/24 provoked abortion
Habal et al. [37] 2013 IFX/ADA PC/P(T1-T3) Case series (29 pregnancies in 21 women) Unknown 27 normal, healthy, full term; 2 miscarriages
Traussnigg et al. [39] 2013 IFX/ADA PC/P(T1-T3) Case series (14 pregnancies in 13 women) Unknown 13 normal, healthy, full term; 1 miscarriage
Zelinkova Z et al. [12] 2013 IFX/ADA PC/P(T1-T3)
(T1-T2 ADA only)
Case series (31 pregnancies in 28 women) Unknown 28 live births (27 normal, healthy, full term; 1
child born to a mother treated with
concomitant methotrexate periconceptually
had polydactyly); 3 miscarriages
Casanova et al. [48] 2011 IFX/ADA/CZP PC/P(T1-T3) Case-controlled retrospective study
(30 pregnancies in treated mothers
versus 110 unexposed IBD pregnancies)
Unknown Prevalence of unfavorable delivery outcome
(spontaneous abortion, preterm delivery, low
birth weight and malformations) were higher
in the control group
Seirafi et al. [52] 2011 IFX/ADA/CZP PC/P(T1-T3) Case series (85 women) Unknown 6/85 were miscarriages, 47/85 were live births
(30/85 ongoing), 8/49 were preterm, 3/49
were deaths (two in utero/one very
premature),7/46 live births had neonatal
complications (1 infection, 3 respiratory
distress syndrome, 6 LBW <2500 g, 1
HELLP syndrome
Mahadevan et al. [51] 2012 IFX/ADA/CZP PC/P(T1-T3) Case-controlled study (291 women
without, and 79 with immunomodulators)
Unknown No increased risk apart from higher risk of
spontaneous abortion and C-section in group
treated with biologics alone, and higher risk
of preterm birth and infections int offspring
at 12 months in combined thiopurine group
verus biologics-alone group or unexposed
IBD pregnancies
Casanova et al. [35] 2013 IFX/ADA/CZP PC/P(T1-T3) Case series (66 pregnancies) Unknown 55 normal, healthy full term;, 4 preterm; 6
miscarriages; 1 congenital abnormality
(several cardiac malformations)
Mahadevan et al. [17] 2013 IFX/ADA/CZP PC/P(T1-T3) Case series (31 women) 15 vaginal, 16 C-section All 33 children (2 sets of twins) were normal,
healthy, full term
Abbreviations: 5-ASA 5-aminosalicylic acid, ADA adalimumab; C-section cesarean section, CZP certolizumab pegol, HELLP a syndrome characterized by hemolysis, elevated liver enzymes, and low platelet count (that is, a
variant/complication of pre-eclampsia), IBD inflammatory bowel disease, IFX infliximab, LBW low birth weight, PC periconceptual (that is, use within 90 days before conception), PP post-partum, P(T1-T3) (pregnancy
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http://www.biomedcentral.com/1741-7015/11/174(RR) for preterm birth was found for women on combin-
ation therapy (2.4; 95% confidence interval (CI) 1.3 to
4.3), which was, however, not found for those on bio-
logics only (0.8; 95% CI, 0.5 to 1.3). No elevation in the
risk of spontaneous abortion, low birth weight, or con-
genital abnormalities was observed for biologics, either
alone or in combination with thiopurines. Earlier reports
(May 2012) had indicated that there was a higher rate of
infections in the offspring [51], but the RR at month 12,
adjusted for premature birth, was shown in April 2013
to be 0.9 (95% CI 0.7 to 1.1) for biologics alone, and 1.0
(95% CI 0.7 to 1.3) for those on combined therapy.
When results for CZP were excluded, the values were
0.9 (95% CI 0.8 to 1.2) and 1.0 (95% CI 0.7 to 1.3), re-
spectively [53]. In addition, breast feeding was not asso-
ciated with any risk of infection or impairment of height
or weight. The limitation on the preliminary data was
that not all infants had reached the age of 12 months,
and the observation will continue until the age of 4 years
for all of the offspring [53].
The French GETAID consortium prospectively recorded
pregnant women with IBD during a 2 year period (2009 to
2010), and preliminary data analysis of 127 pregnancies in
120 women was reported in 2010 [52]. Of these 120
women, 54 women had received biologic therapy for their
IBD. Birth outcomes of the women on biologics did not
differ from those in the unexposed IBD population,
suggesting an absence of any excess risk linked to anti-
TNF-α therapy.
Schnitzler et al. [54] conducted an observational study
of 35 pregnancies under direct exposure to IFX until
week 20 of pregnancy, 53 pregnancies with indirect ex-
posure to IFX (women treated with IFX prior to preg-
nancy), 7 pregnancies with direct exposure to ADA, and
56 matched pregnancies in healthy women. Several pa-
tients experienced a flare of disease in the third trimes-
ter. However, exposure to anti-TNF-α preparations was
not associated with a higher incidence of adverse preg-
nancy outcomes [54]. The paper concluded that preg-
nancy outcomes after exposure to TNF inhibitors did
not differ from those of women with IBD who were not
exposed to anti-TNF treatment, but were worse than in
healthy women [54]. Further, a literature review includ-
ing women with rheumatic disorders or CD with direct
exposure to IFX at any time during pregnancy did not
find any increase in undesirable pregnancy or fetal out-
come [55].
However, in contrast to studies providing evidence of
the safety of anti-TNF-α preparations during pregnancy,
a review of more than 120,000 adverse events voluntarily
reported to the FDA after drug exposure revealed 61
congenital abnormalities in 41 children of 40 mothers
exposed to TNF-α blockers for various indications, in-
cluding IBD [56]. Of these, 22 mothers were exposed toetanercept (a biologic agent not efficacious for IBD [57]),
and 19 were exposed to IFX. Of the 41 children, 24
(59%) had abnormalities thought to be part of the
VACTERL (vertebral abnormalities, anal atresia, cardiac
defects, tracheoesophageal, renal and limb abnormal-
ities) spectrum. The findings led the authors to conclude
that the use of TNF-α blockers should be avoided during
pregnancy. However, this study was subsequently criti-
cized for significant methodological flaws [58,59], in-
cluding selection bias, lack of a control group, and the
fact that only one of the infants (the etanercept group
only) had a clustering of three or more abnormalities
included in the VACTERL spectrum [60]. Furthermore,
the review did not take into account the total number
of women exposed to anti-TNF-α agents or any
confounding by severity of the underlying disease. Fi-
nally, the most common defects reported in this review
were cardiac defects, which are observed in the general
population as well [58,59].
Like other IgG antibodies, IFX is transferred across
the placenta with the help of an Fc receptor neonatal
(FcRn) molecule responsible for the transfer of immuno-
globulins from the mother to the neonate [11]. The
transfer occurs partly in the second, and mainly in the
third trimester [31]. This finding has led many clinicians
to discontinue IFX in the third trimester when the
highest level of transfer occurs [61], in the belief that de-
tectable serum IFX in the neonate might lead to clinic-
ally relevant immunosuppression. Moreover, the use of
biologics in the second and third trimesters has been
questioned [12]. However, Zelinkova et al. [12,50]
showed that even though two patients discontinued IFX
treatment as early as in week 26 of pregnancy, the in-
fants still had detectable amounts of IFX in their serum
samples after delivery. Low levels of IFX have been
detected up to 6 months post-partum in the serum of
infants whose mothers have received this drug up to de-
livery [16]. IFX was undetectable in the infant at delivery
only in one case, where the mother discontinued drug
therapy at week 21, suggesting that discontinuation of
drug therapy might be considered earlier than the begin-
ning of the third trimester [50].
Because of this presence of IFX in the circulation after
delivery, the use of live-virus vaccines (for example,
varicella, measles, mumps, rubella, rotavirus, intranasal
influenza, and bacillus Calmette-Guérin; BCG) is contra-
indicated in patients receiving biologic therapy and their
children [62]. A case report described a fatal incident of
an infant who was exposed to IFX during gestation and
who received a BCG vaccine at 3 months; this infant died
of disseminated BCG infection [63]. Thus, the most recent
recommendation from the World Congress of Gastro-
enterology consensus statement on vaccinations in infants
exposed to biologic therapy in utero recommend delay of
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longer detectable in the child’s blood [62].
In this systematic review, identifying 17 case reports re-
lated to IFX [14,16,20,22,23,29,30,33,34,40,41,45,47,63-66],
13 case series [12,17,19,28,32,37-39,42,43,46,67,68], 2 un-
controlled cohort studies [19,36, and 2 controlled cohort
studies [48,69] (Table 2), we found the prevalence of
pregnancy complications, including preterm delivery,
stillbirth, low birth weight, miscarriages, or congenital
malformations in children exposed to IFX throughout
pregnancy is limited, even after exposure to biologics
throughout the third trimester. However, the use of IFX
up to week 30 of gestation results in fetal intra-uterine ex-
posure to high IFX levels (up to three-fold higher than in
the maternal peripheral blood), which may raise concerns
about the long-term effects of IFX on these children, in-
cluding effects on their immune system [50].
Adalimumab
The clinical data for the safety of ADA during pregnancy
in women with IBD are more limited than for IFX, but
in animals, it appears that ADA does not increase ob-
stetric risks and has no teratogenic effects [70]. In
humans, data on ADA and pregnancy primarily con-
cerns patients with diseases other than IBD, such as
rheumatoid arthritis and psoriasis.
For IBD, 21 case reports and series with more than
300 children exposed showed no increased risk of ad-
verse pregnancy outcome or congenital malformations
associated with ADA treatment during pregnancy com-
pared with pregnancies in unexposed women with IBD
[12,17,19,35,37,39,43,46,48,51,52,54,71-80], even if ADA
was administered in the third trimester [17,19,35,37,39,
43,46,48,51,52,71-74,76,77,79,80]. The Organization of
Teratology Information Specialists reported on a group
of 34 women treated with ADA for various indications
in a prospective study, and another 133 ADA-exposed
women in a case series. There was no difference in pre-
term deliveries, stillbirths, spontaneous abortions or
congenital malformations in the group treated with
ADA compared with either the general population or a
control group with the same disease but not exposed to
ADA [62,81]. In line with these observations, Schnitzler
et al. did not find a higher incidence of adverse preg-
nancy outcomes in seven women treated with ADA
compared with unexposed women with IBD, although
the power of that study was limited [54].
An ongoing cohort study evaluating ADA in pregnancy
compared 80 live offspring born to 94 ADA-exposed
women with CD, 53 live offspring of 58 women with CD
not exposed to ADA, and 78 of 87 women from a non-
diseased comparison group. The frequency of congenital
abnormality in the three groups was 9.6%, 5.4%, and 5.0%,
respectively [72] (P>0.05 between all groups).Like IFX, ADA is transferred across the placenta in
the third trimester of pregnancy [31,76], and accord-
ingly, it has been recommended at many IBD centers
that ADA should be discontinued in the third trimester
(that is, week 30), even though data, as mentioned be-
fore, do not support this theory [82].
Osting et al. carried out a review of TNF-α blockers
(ADA and eternacept only) administered during preg-
nancy from 1999 to 2009 using the Organization of
Tetratology Information Specialists (OTIS) prospective
registry, and concluded that 7 to 10% of children had
congenital abnormalities [83]. However, the underlying
disease activity might be a confounding factor with
greater effect on the risk of congenital abnormalities
than the biologic treatment per se.
Golimumab
Because GLM was approved only recently (May 2013)
by the FDA for treatment of the UC, data are not yet
available for this drug in relation to IBD pregnancies.
Certolizumab pegol
Because CZP lacks the Fc portion of the antibody, which
is crucial for the main transfer of immunoglobulins
across the placenta, the transfer of CZP to the offspring
is low, but a small transfer of Fab fragments is seen [31].
In a group of 10 women receiving CZP during preg-
nancy, with the final dose 1 to 4 weeks before delivery,
CZP was detectable at minimal levels in the infants’ cir-
culation [17]. Overall, CZP is transferred across the pla-
centa to a much lower degree than IFX or ADA [17].
Compared with the other two TNF inhibitors ap-
proved for CD, the human data on pregnancy outcomes
in mothers treated with CZP during pregnancy are more
limited. In three case reports where CZP injections were
administered during the third trimester, healthy infants
were delivered at full term [84-86], and in a case series
of 16 pregnancies of CZP-treated mothers, all children
were healthy [31]. In a recent case series with 139 preg-
nancies, 17 were in mothers with rheumatoid arthritis;
of these 139 pregnancies, 103 ended in live birth (2 with
congenital abnormalities; see Table 1), 21 in spontaneous
miscarriage, and 15 in elective termination [87], results
that are similar to those reported in the general popula-
tion [87]. Based on these findings and the low placental
transfer of CZP, the drug appears to be safe to use
throughout pregnancy [17]. One of the reports observed
uterine bleeding in the mother at 7 days post-partum;
whether this can be ascribed to the CZP treatment re-
mains to be established [86].
Evaluation of the identified studies
In the studies included in this systematic review, more
than 1,426 live births occurred among all the women
Table 2 Studies reporting exact numbers, odds ratios, or relative risks for various birth outcomes in women with IBD exposed to TNF-α blockers compared
with unexposed controls with IBD




Preterm delivery Low birth weight Abnormalities/major birth
defects/malformations
Infections during the
first 12 months of life
Johnson et al. [72] 34a 55b 5/34 versus 3/55; OR 2.99
(95% CI 0.67 to 13.41)
− − 2/34 versus 2/53; OR
1.59 (0.21 to 11.9)
−
Schnitzler et al. [54] 42 78 9/42 versus 12/78; OR 1.5
(0.57 to 3.92)
8/32 versus 8/65;
OR 2.38 (0.80 to 7.06)
6/32 versus 9/65; OR
1.44 (0.46 to 4.46)
1/42 versus 1/78; OR
1.87 (0.11 to 30.8)
−
Casanova et al. [48] 202c 110 20/202 versus 19/110;
OR 0.53 (0.27 to 1.04)
8/202 versus 13/110;
OR 0.31 (0.12 to 0.77)
12/202 versus 11/110;
OR 0.57 (0.24 to 1.33)
2/202 versus 0/110;
(no OR or CI)
−
Mahadevan et al. [51] 79c 291/326 RR 1.29 (0.79 to 2.11);
Biologics alone:; RR 2.56
(1.07 to 4.12)
RR 1.83 (1.01 to 3.31);
Biologics alone:; RR 0.89
(0.54 to 1.47)
− − RR 1.35 (1.01-1.80); Biologics
alone:; RR 0.89 (0.70-1.12)
Abbreviations: CI confidence interval, IBD inflammatory bowel disease, OR odds ratio, RR relative risk, TNF tumor necrosis factor.
aPatients with Crohn’s disease, psoriasis, rheumatoid arthritis, and other forms of arthritis.
bControls were unexposed patients with rheumatoid arthritis.
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tal abnormalities associated with live births reported did
not point to any pattern of specific birth defects
(Table 1). There were 128 miscarriages, 81 elected abor-
tions (presumably ‘under-reported’), 12 stillbirths, and
33 preterm births reported (Table 1).
Owing to considerable variation in study designs, se-
lection of controls, and the definition and selection of
outcomes in the identified studies, we were unable to
conduct a meta-analysis. However, it appears clear from
Table 2 that for all outcomes except congenital abnor-
malities, the OR or RR did not point systematically to-
wards a negative or positive effect of TNF-α inhibitors.
A slightly increased risk of congenital abnormalities in
women with IBD exposed to TNF-α inhibitors compared
with unexposed pregnant women with IBD seemed to be
suggested from the few studies with controls (Table 2),
but the CIs were very broad. Moreover, this observation
should be weighed against the fact that the vast majority
of case reports did not report congenital abnormalities,
although it is thought that such ‘positive’ cases are more
likely to be described and published than negative ones.
Lastly, the meta-analysis by Cornish et al. [1] including
3,907 women with IBD, showed that an underlying in-
creased risk of the studied outcomes already exists (still-
births: OR 1.48 (95% CI 0.89 to 2.47); preterm delivery:
OR 1.87 (1.52 to 2.31); low birth weight: OR 2.10 (1.38
to 3.19); and congenital abnormalities: OR 2.37 (1.47 to
3.82)) independent of treatment, compared with 320,531
pregnant non-IBD controls.
Discussion
When summarizing the existing data in this systematic
review, no association between treatment with TNF-α in-
hibitors for IBD in pregnancy and adverse pregnancy out-
comes such as spontaneous abortions, preterm deliveries,
stillbirth, low birth weight, congenital malformations, and/
or infections, was found, even after administration of
TNF-α blockers in the third trimester. In studies combin-
ing biologics with thiopurines (which often occurs because
of the favorable results of the Study of Immunomodulator
Naïve Patients in Crohn’s disease (SONIC) [88] and UC
SUCCESS (a study similar to the SONIC trial) [89] studies
in CD and UC, respectively), there was no increased risk
of infections in newborns compared with an unexposed
control group.
Ideally, any woman with IBD intending a pregnancy
should have counseling with her gastroenterologist and
obstetrical provider well in advance of conception, and
this counseling should cover the medical treatment
options and the risks associated with active disease dur-
ing pregnancy. Pregnancy should if possible be planned,
and the IBD should be controlled before conception.
Further, the importance of adherence to treatment andprevention of relapse during pregnancy should be
stressed, and the patient should be monitored as a high-
risk pregnancy. However, in real-world situations, this is
not always the case, but it is important for the physician
to discuss with each patient with IBD the risk versus
benefit ratio of medical therapy, including TNF-α inhibi-
tors, for disease control during pregnancy.
Embryo-fetal perinatal developmental toxicity studies
performed in cynomolgus monkeys receiving doses of
TNF-α inhibitors several hundred times the recommended
human dose did not reveal any evidence of teratogenic
or other deleterious effects [90], such as adverse pregnancy
or maternal outcomes [91]. Because IFX does not
cross-react with TNF-α in species other than humans and
chimpanzees, other animal reproduction studies have not
been conducted with this drug. Thus, to date there is
no evidence that TNF blockers are associated with
embryotoxicity, teratogenicity, or increased pregnancy loss
compared with pregnancies unexposed to biologics, either
in rheumatology [92], or in a recent retrospective IBD mul-
ticenter study [35].
The present systematic literature review reveals that
many reports on biologic treatment in pregnancy lack
information on the total number of women exposed to
treatment, disease activity, co-morbidities, and/or con-
comitant medications. In some cases, it is therefore diffi-
cult to establish whether instances of fetal harm are due
to medications or to the severity of the underlying illness
[20,21]. Furthermore, many of the studies intending
to assess the effect of TNF-α inhibitors per se were
confounded by the fact that many patients are on mul-
tiple medications. Finally, it should be kept in mind that
biologics are more commonly used in patients with
more severe disease activity, which accordingly might
influence the pregnancy outcome data presented [1], es-
pecially if patients are not compared with pregnant
women with a similar degree of IBD disease severity
treated with other medications. As an example, the un-
favorable outcome described by Srinivasan [21] may po-
tentially be due to the underlying severity of IBD or to
other medications.
The aggravation of underlying disease might be more
detrimental to the viability of pregnancy than the appar-
ently low risk of continuing biologic therapies, and the
results from this systematic review do not support the
practice of stopping biologic treatment of the expectant
mother after week 30 because of a theoretical risk of in-
fections or congenital abnormalities in the offspring.
The data presented here suggest that the rates of con-
genital malformations and adverse birth events are simi-
lar to the rates in the background population of
pregnant women, or at least of women with IBD in gen-
eral [1]. Further, there is no increased risk of infections
in the offspring of mothers on biologic treatment during
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munosuppression of the offspring contraindicate the use
of live vaccines until the biologic agent is no longer de-
tectable in the child’s circulation, because of the risk of
fatal infections [63,93,94].
Limitations of the study
Limitations of studies identified in this systematic review
included small sample sizes and paucity of studies with
control groups. Future studies assessing the outcome of
pregnancies exposed to IFX or other biologics during
conception and pregnancy should be prospective in na-
ture, and should assess comparable women with IBD
with or without the relevant exposure as a control group
to draw firm conclusions. Data on potential con-
founders, especially maternal age, disease activity, and
co-medications, should also be recorded. Furthermore,
long-term follow-up studies of children exposed to bio-
logic medications in the uterus should be carried out, es-
pecially as no long-term data exist on outcomes in
children related to the development of diseases such as
asthma or autoimmune diseases.
Conclusions
There is a growing body of evidence suggesting that bio-
logic agents are of low risk in pregnancy. Although it is
difficult to prove absolute safety, this systematic review
suggests that women who inadvertently become preg-
nant while taking TNF-α inhibitors can be reassured that
continuation of pregnancy does not appear to impose an
increased risk to either themselves or their baby. The
limited clinical results available suggest that the benefit
of biologic agents in attaining response and maintaining
remission in pregnant women with IBD might outweigh
the risk of pregnancy complications due to flare-ups (for
example, spontaneous abortions, prematurity, low birth
weight or stillbirth), and the theoretical risk of drug ex-
posure to the fetus [34]. However, the long-term impli-
cations of fetal exposure to therapeutic monoclonal
antibodies on the child’s developing immune system are
still unknown.
Therefore, biologics should be discontinued during
pregnancy only if the IBD of the pregnant patient is in
remission using stopping criteria for patients with IBD
in general, and the intentional use of biologics through-
out pregnancy should be considered in situations where
the disease is active at the end of the second trimester,
as a documented benefit of TNF-α inhibitors for active
inflammatory and fistulizing IBD is unprecedented. Fur-
ther prospective studies are essential to elucidate the risk
of combination therapy on the neonatal immune system.
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